Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Next Previous
Trial Profile

A Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary) ; Fianlimab (Primary) ; Pembrolizumab
  • Indications Malignant melanoma; Skin cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Regeneron Pharmaceuticals

Most Recent Events

  • 30 Oct 2024 Planned number of patients changed from 1590 to 1535.
  • 30 Oct 2024 Planned End Date changed from 31 Aug 2032 to 30 Jun 2031.
  • 30 Oct 2024 Planned primary completion date changed from 3 Mar 2026 to 30 Jun 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top